Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker XRPN
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 23, 2026 | XRPN Evernorth Holdings Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 23, 2026 | XRPN Evernorth Holdings Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 13, 2026 | XRPN Evernorth Holdings Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 13, 2026 | XRPN Evernorth Holdings Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 5.06 Change in Shell Company Status | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 5.05 Amendments to the Code of Ethics, or Waiver of a Provision | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 5.01 Changes in Control of Registrant | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 2.01 Completion of Acquisition or Disposition of Assets | 8-K | 8-K ↗ |
| Oct 9, 2026 | XRPN Evernorth Holdings Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 6, 2026 | XRPN Evernorth Holdings Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 5, 2026 | XRPN Evernorth Holdings Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Sep 17, 2026 | XRPN Evernorth Holdings Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Sep 17, 2026 | XRPN Evernorth Holdings Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Sep 17, 2026 | XRPN Evernorth Holdings Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
20 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances